SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Janka G. Hemophagocytic syndromes. Blood Rev 2007; 21: 24553.
  • 2
    Henter J, Horne A, Arico M, Egeler R, Filipovich A, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 12431.
  • 3
    Stephan J, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur A. Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology (Oxford) 2001; 40: 128592.
  • 4
    Sawhney S, Woo P, Murray K. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85: 4216.
  • 5
    Kelly C, Salvi S, McClain K, Hayani A. Hemophagocytic lymphohistiocytosis associated with precursor B acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 56: 65860.
  • 6
    Pringe A, Trail L, Ruperto N, Buoncompagni A, Loy A, Breda L, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? Lupus 2007; 16: 58792.
  • 7
    Parodi A, Davi S, Pringe AB, Pistorio A, Ruperto N, Magni-Manzoni S, et al, for the Lupus Working Group of the Paediatric Rheumatology European Society. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 2009; 60: 338899.
  • 8
    Grom A. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol 2003; 15: 58790.
  • 9
    Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009; 15: 1614.
  • 10
    Son MB, Gauvreau K, Ma L, Baker AL, Sundel RP, Fulton DR, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009; 124: 18.
  • 11
    Weiss PF, Klink AJ, Hexem K, Burnham JM, Leonard MB, Keren R, et al. Variation in inpatient therapy and diagnostic evaluation of children with Henoch Schonlein purpura. J Pediatr 2009; 155: 81218.e1.
  • 12
    Weiss PF, Klink AJ, Localio R, Hall M, Hexem K, Burnham JM, et al. Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schonlein purpura. Pediatrics 2010; 126: 67481.
  • 13
    Child Health Corporation of America. URL: http://www.chca.com/index_no_flash.html.
  • 14
    Conway PH, Keren R. Factors associated with variability in outcomes for children hospitalized with urinary tract infection. J Pediatr 2009; 154: 78996.
  • 15
    Goldin AB, Sawin RS, Garrison MM, Zerr DM, Christakis DA. Aminoglycoside-based triple-antibiotic therapy versus monotherapy for children with ruptured appendicitis. Pediatrics 2007; 119: 90511.
  • 16
    Turney CM, Wang W, Seiber E, Lo W. Acute pediatric stroke: contributors to institutional cost. Stroke 2011; 42: 321925.
  • 17
    Hickey PW, Cape KE, Masuoka P, Campos JM, Pastor W, Wong EC, et al. A local, regional, and national assessment of pediatric malaria in the United States. J Travel Med 2011; 18: 15360.
  • 18
    National Center for Health Statistics and the Centers for Medicare and Medicaid Services. Conversion Table of New ICD-9-CM Codes, October 2011. URL http://www.cdc.gov/nchs/data/icd9/CNVTB12.pdf.
  • 19
    Gupta AA, Tyrrell P, Valani R, Benseler S, Abdelhaleem M, Weitzman S. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution. J Pediatr Hematol Oncol 2009; 31: 814.
  • 20
    Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146: 598604.
  • 21
    Yamazawa K, Kodo K, Maeda J, Omori S, Hida M, Mori T, et al. Hyponatremia, hypophosphatemia, and hypouricemia in a girl with macrophage activation syndrome. Pediatrics 2006; 118: 255760.
  • 22
    Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 2011; 17: 237.
  • 23
    Kumar S, Vaidyanathan B, Gayathri S, Rajam L. Systemic onset juvenile idiopathic arthritis with macrophage activation syndrome misdiagnosed as Kawasaki disease: case report and literature review. Rheumatol Int 2010. E-pub ahead of print.
  • 24
    Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007; 56: 3793804.
  • 25
    Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56: 96571.
  • 26
    Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34: 11338.
  • 27
    Keren R, Wheeler A, Coffin SE, Zaoutis T, Hodinka R, Heydon K. ICD-9 codes for identifying influenza hospitalizations in children. Emerg Infect Dis 2006; 12: 16034.